Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nitric Oxide for Tinea Pedis
NCT00893880Phase 2Completed
- Sponsor
- Nitric BioTherapeutics
- Start
- Jun 2009
- Primary completion
- Jan 2010
- Modality
- DNA Intercalators/Alkylators, Inhalation Devices
- Countries
- 2
01
Overview
Phase 2, open-label trial of nitric oxide in tinea pedis (4 arms), sponsored by Nitric BioTherapeutics. Primary endpoints: Complete cure at 29 days, Effective treatment at 29 days and 1 more. Started Jun 2009; status: completed.
02
Drugs
nitric oxide
03
Conditions
tinea pedis
Beyond the preview
Go deeper on NCT00893880.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00893880.